PDS Biotechnology Co. (NASDAQ:PDSB – Get Rating) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,820,000 shares, a growth of 15.2% from the February 13th total of 1,580,000 shares. Based on an average trading volume of 606,100 shares, the days-to-cover ratio is currently 3.0 days.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on PDSB shares. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Tuesday, February 28th. Noble Financial lifted their price target on shares of PDS Biotechnology to $19.00 in a research report on Monday, November 28th. Finally, B. Riley lifted their price target on shares of PDS Biotechnology from $10.00 to $12.00 in a research report on Wednesday, December 28th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $16.80.
PDS Biotechnology Trading Up 2.9 %
PDS Biotechnology stock opened at $7.00 on Wednesday. The firm’s 50 day moving average price is $8.73 and its two-hundred day moving average price is $7.16. PDS Biotechnology has a 1 year low of $2.89 and a 1 year high of $13.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 15.37 and a current ratio of 15.37. The firm has a market cap of $199.22 million, a price-to-earnings ratio of -6.93 and a beta of 2.31.
Hedge Funds Weigh In On PDS Biotechnology
About PDS Biotechnology
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.
- Get a free copy of the StockNews.com research report on PDS Biotechnology (PDSB)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.